Summary & Overview
HCPCS J0874: Daptomycin (Baxter) Injection, 1 mg
HCPCS Level II code J0874 denotes an injectable dose of daptomycin (Baxter), reported per 1 mg and identified as not therapeutically equivalent to J0878. Daptomycin is a parenteral antibiotic used in serious Gram-positive bacterial infections; accurate coding for the specific product is essential for claims processing, inventory management, and drug cost monitoring. Nationally, precise HCPCS reporting matters for reimbursement consistency and for tracking utilization of branded versus non-branded or non-equivalent products.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a compact review of clinical context for daptomycin use, the service settings where J0874 is typically billed, and the types of benchmarks and policy elements that affect coverage and payment. The publication outlines reimbursement benchmark categories, coding nuances tied to product equivalence, and common billing modifiers used with single-source injectable drugs. It also highlights policy and billing trends that influence payer adjudication, prior authorization practices, and facility versus professional billing distinctions.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related procedure or diagnosis codes is noted where applicable. The goal is to provide clinicians, coders, and policy staff a concise reference to the clinical and billing implications of HCPCS Level II code J0874.
Billing Code Overview
HCPCS Level II code J0874 describes an injection of daptomycin (Baxter), specified as not therapeutically equivalent to J0878, billed per 1 mg. This code represents the drug product and the unit of service for administration-related billing.
Service type: Drug administration — parenteral antibiotic (injectable daptomycin)
Typical site of service: Hospital outpatient department, physician office, infusion center, or other outpatient infusion settings
Clinical & Coding Specifications
Clinical Context
A typical patient is a 62-year-old male admitted to the hospital with suspected Gram-positive bacteremia complicated by an infected prosthetic joint. Blood cultures grow methicillin-resistant Staphylococcus aureus (MRSA) or Enterococcus species susceptible to daptomycin. After infectious disease consultation, the patient is prescribed intravenous daptomycin (manufacturer-specific product billed with J0874) dosed per weight and renal function. The clinical workflow includes: admission evaluation, laboratory testing (blood cultures, basic labs, creatine kinase), baseline assessment of renal function, order entry for the daptomycin infusion, pharmacy preparation of the manufacturer-specific vial billed as J0874 per milligram, bedside IV infusion by nursing in an inpatient ward or observation unit, monitoring for myopathy and eosinophilic pneumonia, and follow-up infectious disease and orthopedics assessments. Typical sites of service are inpatient hospital (acute care), inpatient rehabilitation, and observation stays; outpatient infusion centers or hospital outpatient departments may also administer the drug for continuation of therapy following stabilization.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/unused portion | Use when part of a single-use vial of daptomycin is discarded and documentation supports billing for only the administered amount while reporting discarded portion per payor rules. |